Top Analysts Pick: 3 Stocks to Buy Now for Significant Upside
ByAinvest
Thursday, Jul 24, 2025 6:01 am ET1min read
BLZE--
Crinetics Pharmaceuticals (CRNX)
H.C. Wainwright has reiterated its Buy rating and $81.00 price target on Crinetics Pharmaceuticals (CRNX), representing a substantial 159.5% upside from the current price of $31.11 [1]. The research firm highlighted strong enthusiasm from expert endocrinologists toward Crinetics' lead drug candidate, paltusotine. The drug has demonstrated consistent biochemical and symptom control in acromegaly patients, with a once-daily dosing regimen as a key advantage.
Backblaze (BLZE)
Backblaze (BLZE) has also received a new Buy rating, with a 102.95% upside potential. The company recently announced its second quarter 2025 financial results will be released on August 7, 2025 [2]. Backblaze has been recognized for its cost-effective cloud storage solutions, with an independent report by Enterprise Strategy Group (ESG) demonstrating up to 3.2x lower total cost of ownership (TCO) compared to traditional providers [2].
DraftKings (DKNG)
DraftKings (DKNG) received a new Buy rating with a 22.37% upside. The stock has been gaining attention for its growth potential in the sports betting and daily fantasy sports (DFS) sectors. The company continues to expand its offerings and partnerships, contributing to its positive outlook.
Investors seeking more opportunities like these can use the TipRanks' Analyst Top Stocks tool to find additional stocks with strong analyst support.
References:
[1] https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-crinetics-stock-at-81-price-target-93CH-4143703
[2] https://www.stocktitan.net/news/BLZE/
CRNX--
DKNG--
Three stocks to buy now, according to top analysts, include Crinetics Pharmaceuticals (CRNX) with a 159.5% upside, Backblaze (BLZE) with a 102.95% upside, and DraftKings (DKNG) with a 22.37% upside. The stocks received new Buy ratings recently and have significant potential for growth. TipRanks' Analyst Top Stocks tool can help investors find more stocks like these.
Top analysts have recently issued new Buy ratings for three stocks, each with significant upside potential. Crinetics Pharmaceuticals (CRNX) stands out with a 159.5% upside, followed by Backblaze (BLZE) at 102.95%, and DraftKings (DKNG) with a 22.37% upside.Crinetics Pharmaceuticals (CRNX)
H.C. Wainwright has reiterated its Buy rating and $81.00 price target on Crinetics Pharmaceuticals (CRNX), representing a substantial 159.5% upside from the current price of $31.11 [1]. The research firm highlighted strong enthusiasm from expert endocrinologists toward Crinetics' lead drug candidate, paltusotine. The drug has demonstrated consistent biochemical and symptom control in acromegaly patients, with a once-daily dosing regimen as a key advantage.
Backblaze (BLZE)
Backblaze (BLZE) has also received a new Buy rating, with a 102.95% upside potential. The company recently announced its second quarter 2025 financial results will be released on August 7, 2025 [2]. Backblaze has been recognized for its cost-effective cloud storage solutions, with an independent report by Enterprise Strategy Group (ESG) demonstrating up to 3.2x lower total cost of ownership (TCO) compared to traditional providers [2].
DraftKings (DKNG)
DraftKings (DKNG) received a new Buy rating with a 22.37% upside. The stock has been gaining attention for its growth potential in the sports betting and daily fantasy sports (DFS) sectors. The company continues to expand its offerings and partnerships, contributing to its positive outlook.
Investors seeking more opportunities like these can use the TipRanks' Analyst Top Stocks tool to find additional stocks with strong analyst support.
References:
[1] https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-crinetics-stock-at-81-price-target-93CH-4143703
[2] https://www.stocktitan.net/news/BLZE/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet